Advertisement

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients

Allistair A. Abraham, Tami D. John, Michael D. Keller, C. Russell Y. Cruz, Baheyeldin Salem, Lauren Roesch, Hao Liu, Fahmida Hoq, Bambi J. Grilley, Adrian P. Gee, Hema Dave, David A. Jacobsohn, Robert A. Krance, Elizabeth. J. Shpall, Caridad A. Martinez, Patrick J. Hanley and Catherine M. Bollard
This article has an Erratum 3(16):2453

Article Information

Citation 
vol. 3 no. 14 2057-2068
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted March 25, 2019
  • Accepted June 3, 2019
  • Published online July 10, 2019.


Contributors 
  • Allistair A. Abraham, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Tami D. John, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and
  • Michael D. Keller, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • C. Russell Y. Cruz, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Baheyeldin Salem, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Lauren Roesch, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Hao Liu, 4Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
  • Fahmida Hoq, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Bambi J. Grilley, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and
  • Adrian P. Gee, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and
  • Hema Dave, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • David A. Jacobsohn, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Robert A. Krance, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and
  • Elizabeth. J. Shpall, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and
  • Caridad A. Martinez, 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and
  • Patrick J. Hanley, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;
  • Catherine M. Bollard, 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output